KPT-330 (Selinexor), an oral bioavailable clinical stage SINE class of CRM1 antagonists, demonstrated activities against several solid and hematological cancers including acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL)18,19. The gene discussed is XPO1; the disease is acute lymphoblastic leukemia.